vs

Side-by-side financial comparison of First Bancorp, Inc (FNLC) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $25.8M, roughly 1.4× First Bancorp, Inc). First Bancorp, Inc runs the higher net margin — 39.4% vs -304.2%, a 343.6% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 17.5%). First Bancorp, Inc produced more free cash flow last quarter ($34.6M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 18.1%).

Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

FNLC vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.4× larger
RXRX
$35.5M
$25.8M
FNLC
Growing faster (revenue YoY)
RXRX
RXRX
+664.2% gap
RXRX
681.7%
17.5%
FNLC
Higher net margin
FNLC
FNLC
343.6% more per $
FNLC
39.4%
-304.2%
RXRX
More free cash flow
FNLC
FNLC
$81.9M more FCF
FNLC
$34.6M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
18.1%
FNLC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FNLC
FNLC
RXRX
RXRX
Revenue
$25.8M
$35.5M
Net Profit
$10.2M
$-108.1M
Gross Margin
59.8%
Operating Margin
48.1%
-304.8%
Net Margin
39.4%
-304.2%
Revenue YoY
17.5%
681.7%
Net Profit YoY
39.7%
39.6%
EPS (diluted)
$0.91
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FNLC
FNLC
RXRX
RXRX
Q4 25
$25.8M
$35.5M
Q3 25
$24.5M
$5.2M
Q2 25
$22.5M
$19.2M
Q1 25
$21.8M
$14.7M
Q4 24
$22.0M
$4.5M
Q3 24
$20.5M
$26.1M
Q2 24
$19.2M
$14.4M
Q1 24
$18.5M
$13.8M
Net Profit
FNLC
FNLC
RXRX
RXRX
Q4 25
$10.2M
$-108.1M
Q3 25
$9.1M
$-162.3M
Q2 25
$8.1M
$-171.9M
Q1 25
$7.1M
$-202.5M
Q4 24
$7.3M
$-178.9M
Q3 24
$7.6M
$-95.8M
Q2 24
$6.2M
$-97.5M
Q1 24
$6.0M
$-91.4M
Gross Margin
FNLC
FNLC
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
FNLC
FNLC
RXRX
RXRX
Q4 25
48.1%
-304.8%
Q3 25
45.2%
-3327.6%
Q2 25
43.7%
-916.8%
Q1 25
39.3%
-1297.9%
Q4 24
39.5%
-4042.4%
Q3 24
44.6%
-377.1%
Q2 24
38.8%
-697.4%
Q1 24
39.3%
-698.4%
Net Margin
FNLC
FNLC
RXRX
RXRX
Q4 25
39.4%
-304.2%
Q3 25
37.0%
-3135.3%
Q2 25
35.8%
-894.2%
Q1 25
32.5%
-1373.3%
Q4 24
33.1%
-3935.5%
Q3 24
36.9%
-367.5%
Q2 24
32.1%
-676.6%
Q1 24
32.5%
-662.4%
EPS (diluted)
FNLC
FNLC
RXRX
RXRX
Q4 25
$0.91
$-0.17
Q3 25
$0.81
$-0.36
Q2 25
$0.72
$-0.41
Q1 25
$0.63
$-0.50
Q4 24
$0.66
$-0.56
Q3 24
$0.68
$-0.34
Q2 24
$0.55
$-0.40
Q1 24
$0.54
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FNLC
FNLC
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$95.5M
$9.6M
Stockholders' EquityBook value
$283.1M
$1.1B
Total Assets
$3.2B
$1.5B
Debt / EquityLower = less leverage
0.34×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FNLC
FNLC
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
FNLC
FNLC
RXRX
RXRX
Q4 25
$95.5M
$9.6M
Q3 25
$95.5M
$11.9M
Q2 25
$95.0M
$14.2M
Q1 25
$70.0M
$16.4M
Q4 24
$95.0M
$19.0M
Q3 24
$95.0M
$20.5M
Q2 24
$70.0M
$22.9M
Q1 24
$70.0M
Stockholders' Equity
FNLC
FNLC
RXRX
RXRX
Q4 25
$283.1M
$1.1B
Q3 25
$274.6M
$1.0B
Q2 25
$265.5M
$919.1M
Q1 25
$259.7M
$933.9M
Q4 24
$252.5M
$1.0B
Q3 24
$256.8M
$524.6M
Q2 24
$244.7M
$584.4M
Q1 24
$242.6M
$401.2M
Total Assets
FNLC
FNLC
RXRX
RXRX
Q4 25
$3.2B
$1.5B
Q3 25
$3.2B
$1.4B
Q2 25
$3.2B
$1.3B
Q1 25
$3.2B
$1.3B
Q4 24
$3.2B
$1.4B
Q3 24
$3.1B
$726.5M
Q2 24
$3.1B
$775.9M
Q1 24
$3.0B
$557.8M
Debt / Equity
FNLC
FNLC
RXRX
RXRX
Q4 25
0.34×
0.01×
Q3 25
0.35×
0.01×
Q2 25
0.36×
0.02×
Q1 25
0.27×
0.02×
Q4 24
0.38×
0.02×
Q3 24
0.37×
0.04×
Q2 24
0.29×
0.04×
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FNLC
FNLC
RXRX
RXRX
Operating Cash FlowLast quarter
$37.8M
$-46.1M
Free Cash FlowOCF − Capex
$34.6M
$-47.3M
FCF MarginFCF / Revenue
133.9%
-133.1%
Capex IntensityCapex / Revenue
12.5%
3.5%
Cash ConversionOCF / Net Profit
3.72×
TTM Free Cash FlowTrailing 4 quarters
$55.3M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FNLC
FNLC
RXRX
RXRX
Q4 25
$37.8M
$-46.1M
Q3 25
$12.9M
$-117.4M
Q2 25
$7.4M
$-76.4M
Q1 25
$2.2M
$-132.0M
Q4 24
$26.0M
$-115.4M
Q3 24
$9.8M
$-59.2M
Q2 24
$6.4M
$-82.2M
Q1 24
$-1.5M
$-102.3M
Free Cash Flow
FNLC
FNLC
RXRX
RXRX
Q4 25
$34.6M
$-47.3M
Q3 25
$12.6M
$-117.6M
Q2 25
$7.2M
$-79.6M
Q1 25
$828.0K
$-133.8M
Q4 24
$24.6M
$-116.7M
Q3 24
$9.6M
$-63.8M
Q2 24
$6.3M
$-83.4M
Q1 24
$-1.8M
$-109.0M
FCF Margin
FNLC
FNLC
RXRX
RXRX
Q4 25
133.9%
-133.1%
Q3 25
51.4%
-2272.5%
Q2 25
32.1%
-413.9%
Q1 25
3.8%
-907.4%
Q4 24
111.7%
-2567.7%
Q3 24
47.0%
-244.6%
Q2 24
32.9%
-578.5%
Q1 24
-9.8%
-789.9%
Capex Intensity
FNLC
FNLC
RXRX
RXRX
Q4 25
12.5%
3.5%
Q3 25
1.2%
4.7%
Q2 25
0.6%
16.4%
Q1 25
6.2%
12.4%
Q4 24
6.7%
28.6%
Q3 24
0.5%
17.5%
Q2 24
0.3%
8.2%
Q1 24
1.8%
48.2%
Cash Conversion
FNLC
FNLC
RXRX
RXRX
Q4 25
3.72×
Q3 25
1.42×
Q2 25
0.91×
Q1 25
0.31×
Q4 24
3.58×
Q3 24
1.29×
Q2 24
1.03×
Q1 24
-0.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons